Skip to main content
United Therapeutics Corporation (UTHR)
NASDAQ: UTHR · Real-Time Price · USD
542.66
-0.73 (-0.13%)
At close: Jun 26, 2026, 4:00 PM EDT
542.50
-0.16 (-0.03%)
After-hours: Jun 26, 2026, 6:27 PM EDT

United Therapeutics Revenue by Segment
Period Ending Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020
Tyvaso
1.87B 1.88B 1.83B 1.79B 1.71B 1.62B 1.56B 1.45B
Tyvaso Growth
9.05% 15.91% 17.66% 23.39% 25.33% 31.34% 38.18% 36.87%
Remodulin
515.20M 526.80M 533.30M 535.70M 548.30M 538.10M 518.70M 521.50M
Remodulin Growth
-6.04% -2.10% 2.81% 2.72% 9.35% 8.75% 3.29% 7.50%
Orenitram
511.80M 496.90M 483.50M 465.60M 448.80M 434.30M 410.60M 389.40M
Orenitram Growth
14.04% 14.41% 17.75% 19.57% 18.92% 20.84% 16.95% 12.35%
Unituxin
222.20M 226.80M 232.00M 245.20M 238.50M 238.70M 225.40M 215.60M
Unituxin Growth
-6.83% -4.99% 2.93% 13.73% 14.55% 20.01% 24.26% 22.36%
Adcirca
26.90M 30.00M 26.90M 24.20M 23.40M 23.80M 25.90M 26.20M
Adcirca Growth
14.96% 26.05% 3.86% -7.63% -16.43% -17.65% -20.31% -27.02%
Other
24.30M 24.00M 22.90M 21.50M 20.90M 22.10M 20.50M 16.90M
Other Growth
16.27% 8.60% 11.71% 27.22% 74.17% 166.27% 150.00% 168.25%

Revenue by Geography
Period Ending Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020
United States
3.03B 3.04B 2.99B 2.93B 2.85B 2.74B 2.62B 2.49B
United States Growth
6.45% 10.85% 14.12% 17.90% 19.96% 24.41% 25.96% 24.63%
International
138.20M 145.70M 138.50M 145.40M 146.30M 137.70M 136.30M 129.50M
International Growth
-5.54% 5.81% 1.61% 12.28% 17.70% 9.90% 9.65% 12.32%
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.